PAXMAN publishes newsletter on its new CIPN indication and the double win at the EEF Future Manufacturing Awards
Today, PAXMAN publishes the February 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.
In this issue, PAXMAN’s CEO comments on the company’s new project to develop a cooling device for preventing chemotherapy-induced nerve damage in hands and feet (CIPN) with National University Hospital, Singapore. Additionally, a video is included from PAXMAN’s double win at this year’s EEF Future Manufacturing Awardsin London.
To read the newsletter, and subscribe to receive upcoming issues, follow this link:
PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors,www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
E-mail: richard@paxmanscalpcooling.com
www.paxmanscalpcooling.com
About PAXMAN
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With more than 3,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)
The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.